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BACKGROUND AND PURPOSE
The cysteine-rich head region, which is adjacent to the proposed ATP-binding pocket in the extracellular ligand-binding loop
of P2X receptors for ATP, is absent in the antagonist-insensitive Dictyostelium receptors. In this study we have determined the
contribution of the head region to the antagonist action of NF449 and suramin at the human P2X1 receptor.
EXPERIMENTAL APPROACH
Chimeras and point mutations in the cysteine-rich head region were made between human P2X1 and P2X2 receptors.
Mutant receptors were expressed in Xenopus oocytes and P2X receptor currents characterized using two-electrode voltage
clamp.
KEY RESULTS
The chimera replacing the region between the third and fourth conserved cysteine residues of the P2X1 receptor with the
corresponding part of P2X2 reduced NF449 sensitivity a thousand fold from an IC50 of ~1 nM at the P2X1 receptor to that
of the P2X2 receptor (IC50 ~1 mM). A similar decrease in sensitivity resulted from mutation of four positively charged P2X1
receptor residues in this region that are absent from the P2X2 receptor. These chimeras and mutations were also involved in
determining sensitivity to the antagonist suramin. Reciprocal chimeras and mutations in the P2X2 receptor produced modest
increases in antagonist sensitivity.
CONCLUSIONS AND IMPLICATIONS
These data indicate that a cluster of positively charged residues at the base of the cysteine-rich head region can account for
the highly selective antagonism of the P2X1 receptor by the suramin derivative NF449.
Abbreviation
WT, Wild type
Introduction
P2X receptors comprise a family of ATP-gated cation chan-
nels. Seven mammalian P2X receptor subunits (P2X1 to
P2X7; nomenclature follows Alexander et al., 2011) have
been identiﬁed, and they assemble to form functional homot-
rimeric or heterotrimeric channels (North, 2002). These
receptors mediate physiological processes ranging from pain
sensation to bone formation (Burnstock, 2006). In the car-
diovascular system, P2X1 receptors are expressed on arterial
smooth muscle, contribute to sympathetic nerve-mediated
vasoconstriction (Vial and Evans, 2002) and, in the kidney,
they are essential for autoregulation of blood ﬂow (Inscho
et al., 2003). The receptors are also expressed on platelets
where their activation results in calcium inﬂux and shape
change (Mahaut-Smith et al., 2004; Gachet, 2006). In P2X1
receptor-deﬁcient (knockout) mice, bleeding times are
normal but there is reduced thrombus formation following
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bolism (Hechler et al., 2003). A role for these receptors in
thromboembolism was further supported by increased mor-
tality in mice over-expressing platelet P2X1 receptors follow-
ing i.v. injection of collagen and adrenaline (Oury et al.,
2003). These results highlight the therapeutic potential of
P2X1 receptor antagonists as antithrombotic agents and in
stroke prevention.
One of the ﬁrst P2X receptor antagonists to be described
was suramin (Dunn and Blakeley, 1988). This was originally
used as a trypanocidal drug and also inhibits a range of
enzymes including ATPases (Fortes et al., 1973). Suramin is an
effective antagonist at most P2X receptors with the exception
of P2X4 and P2X7 receptors that are relatively insensitive
(Jarvis and Khakh, 2009). In order to develop P2X subtype-
selective antagonists, a range of suramin derivatives have
been synthesized (Lambrecht et al., 2002; Hausmann
et al., 2006). At the P2X1 receptor, the suramin analogue
NF449 (4,4′,4′′,4′′′-(carbonylbis(imino-5,1,3-benzenetriyl-bis
(carbonylimino)))tetrakis-benzene-1,3-disulphonic acid) has
nanomolar antagonist potency at both recombinant and
native P2X1 receptors (Braun et al., 2001; Hulsmann et al.,
2003; Kassack et al., 2004; Rettinger et al., 2005) and is >1000-
fold more potent at recombinant P2X1 receptors than at
P2X2 receptors (Rettinger et al., 2005). A functional role for
the antagonist was demonstrated for mouse models of throm-
boembolism in vivo where NF449 reduced platelet aggrega-
tion, consistent with blockade of the P2X1 receptor (Hechler
et al., 2005).
The crystallization of the zebraﬁsh P2X4 receptor was a
major advance (Kawate et al., 2009) and has allowed a struc-
tural interpretation of studies addressing the molecular basis
of drug action (Young, 2009; Browne et al., 2010; Evans,
2010). Mapping of mutants that had an effect on ATP
potency onto the structure shows that residues predicted to
form the ATP-binding pocket are clustered at a groove that
forms at the interface between two subunits (Kawate et al.,
2009; Evans, 2010). However, we know comparatively little
about residues involved in antagonist interaction. Species
differences in suramin sensitivity have identiﬁed residue 138
in P2X1 receptors (Sim et al., 2008) and residue 78 in the
P2X4 receptor (Garcia-Guzman et al., 1997) as being impor-
tant. However, the full extent of the suramin-binding site is
unclear, as is the molecular basis for the high selectivity of
NF449 for the P2X1 receptor.
A further clue to where antagonists may act comes from
studies on the Dictyostelium P2X receptors that are insensitive
to suramin (Fountain et al., 2007; Ludlow et al., 2009). There
are 10 conserved cysteine residues in the extracellular loop of
mammalian P2X receptors that are thought to form ﬁve dis-
ulphide bonds. These bonds between the ﬁrst six of these
residues (cysteines 1–6, 2–4 and 3–5) help to give structural
constraint to the ‘head’ region that is adjacent to the pro-
posed ATP-binding site (Figure 1). In Dictyostelium receptors,
a region of >40 amino acids, including conserved cysteine
residues 2–5 in the head region, is absent. These results
suggest that the cysteine-rich head region may contribute to
antagonist action at P2X receptors. To address the role of the
cysteine-rich loop in NF449 and suramin action, we gener-
ated a series of deletion mutants and chimeric receptors
where portions of the cysteine-rich loop region of the human
P2X1 receptor were replaced by the corresponding regions
from the insensitive human P2X2 receptor. Subsequent site-
directed mutagenesis identiﬁed a cluster of positively charged
amino acids that are essential for the nanomolar potency of
NF449 at P2X1 receptors.
Methods
Mutants and chimeras
The human P2X1 receptor construct (Ennion et al., 2000) was
used to generate the deletion mutants Del and DelD using
the QuikChange mutagenesis kit (Stratagene, Amsterdam,
The Netherlands) to remove the equivalent 42 amino
acids missing from the Dictyostelium receptor p2xA,
DDB0168616)(Fountain et al., 2007) or remove the cysteine-
rich loop and replace the sequence between conserved cys-
teines 1 and 6 with the NFTDPT sequence from the
Dictyostelium receptor (DelD mutant)(Figure 1).
To generate the chimeric receptors between the P2X1 and
the P2X2 receptor, megaprimer-mediated domain swapping
was used. The human P2X2 receptor plasmid has been
described previously (Roberts et al., 2008). Initially, the region
to be replaced between the P2X receptors was ampliﬁed by
PCR with an overhang corresponding to the insertion posi-
tion. To accomplish this, forward and reverse primers (Sigma,
Poole, Dorset, UK) were designed to have 25 base pairs of
the region of interest and another 25 base pairs encoding the
overhang adjacent to where the region is to be swapped. The
PCR reaction (50 mL) contained 250 pmol of these primers,
50 ng of template P2X1 or P2X2 receptor, 100 mM of dNTPs
and 2.5 units·mL
-1 of PfuTurbo DNA polymerase (Agilent
Technologies, Cheshire, UK). Each PCR reaction had param-
eters including an initial denaturation step at 95°C for 3 min,
followed by 30 cycles (95°C for 30 s, 55°C for 60 s and 72°C
for 60 s) and a ﬁnal extension at 72°C for 10 min. This PCR
product was puriﬁed (Qiagen, Sussex, UK) and used as a
megaprimer for the second PCR reaction, which used the
corresponding P2X receptor as the backbone template (50 ng
of template, 1 mL of megaprimer, 100 mM of dNTPs and 2.5
units of PfuTurbo DNA polymerase). The PCR parameters had
an initial denaturation at 95°C for 3 min followed by 16
cycles (95°C for 30 s, 55°C for 60 s and 68°C for 16 min) and
a ﬁnal extension at 72°C for 10 min.
Mutations of the residues between Lys
136–Lys
140 in the
P2X1 receptor to the analogous residues in the P2X2 receptor
and vice versa were introduced via the QuikChange
TM
mutagenesis kit (Stratagene, La Jolla, CA, USA). All chimeras
and mutants were veriﬁed by sequencing using Protein and
Nucleic Acid Chemistry Laboratory services, University of
Leicester.
Expression in Xenopus laevis oocytes
cRNAs for wild type (WT), P2X1/P2X2 chimeric and mutant
receptors were produced using the T7 mMessage mMachine
kit (Ambion, Huntingdon, Cambs, UK). Stage V Xenopus
laevis oocytes were prepared and injected with RNA (Digby
et al., 2005). The oocytes were maintained at 18°C in ND96
buffer (concentrations in mM; 96 NaCl, 2 KCL, 1.8 CaCl2,1
MgCl2, 5 sodium pyruvate and 5 HEPES, pH 7.5) with
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-1 gentamicin and were used for recording after 2–6
days. Western blotting, cell surface expression assays were as
described previously (Roberts and Evans, 2004).
Electrophysiological recordings
Two-electrode voltage clamp recordings (at a holding poten-
tial of -60 mV) were carried out on the oocytes using a
Geneclamp 500B ampliﬁer with a Digidata 1322A analogue-
to-digital converter and pClamp 8.2 acquisition software
(Molecular Devices, Menlo Park, CA, USA) (Ennion et al.,
2000). To reduce the action of endogenous calcium-activated
chloride channels in the oocytes, 1.8 mM CaCl2 was replaced
with 1.8 mM BaCl2 in the ND96 bath solution. ATP (Mg
2+ salt)
was applied via a U-tube perfusion system for 3 s at 5 min
intervals. During antagonist applications, NF449 or suramin
were bath perfused in ND96 solution for 5 min before they
were co-applied with an EC90 concentration of ATP through
the U-tube. Full inhibition curves were determined for the
WT, chimeric and mutant P2X receptors with varying con-
centrations of the antagonists and an EC90 concentration of
ATP. NF449 (10 mM) or suramin (100 mM) had no effect on the
holding current of the WT or mutant P2X receptors when
applied in the absence of ATP.
Data analysis
Individual normalized inhibition curves were ﬁtted with the
Hill equation: Y = {(X)
H/[(X)
H + (IC50)
H]} where Y is response, X
is antagonist concentration, H is the Hill coefﬁcient and IC50
is the concentration of antagonist inhibiting the EC90 con-
centration of ATP by 50%. pIC50 is the -log10 of the IC50 value.
For the calculation of IC50 values, individual concentration
response curves were generated for each experiment and sta-
tistical analysis carried out on the pIC50 data generated. In the
ﬁgures, inhibition curves are ﬁtted to the mean normalized
data.
Any signiﬁcant differences between the WTs/chimeras/
mutants (e.g. current amplitude, rise and decay time, Hill
slope, pEC50, and pIC50) were calculated by one-way ANOVA
Figure 1
Contribution of the cysteine-rich head region to P2X1 receptor func-
tion and antagonist action. (A) Amino acid line-up for human P2X1,
P2X2 and the Dictyostelium P2X receptor for the region between
cysteine residues 1–6 that are conserved in most P2X receptors.
Deletions from the P2X1 receptor equivalent to that missing in the
Dictyostelium receptor (P2XA, DDB0168616) are shown (P2X1 recep-
tor sequence-linking cysteines 1–6, Del and with the Dictyostelium
sequence as a linker, DelD). (B) Homology model of the P2X1 recep-
tor based on the zebraﬁsh P2X4 receptor structure. The three sub-
units are shown in black, grey and pink. The cysteine-rich head
region of the black subunit is shown in green. Residues that are
predicted to form the ATP-binding pocket are shown in red. (C) ATP
(100 mM, 3 s application indicated by bar) evoked rapidly desensi-
tizing currents at P2X1 WT receptors but was ineffective at the P2X1
Del mutant. (D) P2X1 WT, Del and DelD mutant receptors are
expressed at equivalent levels. Upper panel shows levels of
sulphoNHS-LC biotin labelled P2X1 receptors and the lower panel
shows total P2X1 receptor levels (representative of three experi-
ments). (E) Effects of NF449 (10 nM) on current evoked by an EC90
concentration of ATP (3 s application indicated by bar) at WT P2X1,
WT P2X2 and chimeric P2X1 Cys2(1–6) receptors. (F) NF449
concentration-dependent inhibition of ATP (EC90 concentration)
evoked currents for WT P2X1, WT P2X2 and chimeric P2X1
Cys2(1–6) receptors (n = 3–6), pIC50 values were 9.07  0.11, 5.86
 0.09 and 6.54  0.07 and Hill slopes were 0.98  0.13, 1.61 
0.08 and 1.38  0.07 respectively.

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Prism 5 (GraphPad Software Inc., San Diego, CA, USA). n  3
for all data points.
The nomenclature for P2X receptors conforms to the
British Journal of Pharmacology Guide to Receptors and
Channels.
P2X1 receptor homology modelling
The trimeric assembly of the human P2X1 receptor (residues
33–352) was modelled in Modeller v9.7 (Marti-Renom et al.,
2000) based on the zebraﬁsh P2X4 structure (PDBid: 3I5D) as
template. Target and template share 44% sequence identity
and 67% sequence similarity based on a BLAST alignment. Out
of the models generated, the best model was selected based
on Modeller’s scoring function and external validation via
Whatcheck (Hooft et al., 1996) and PROSA (Wiederstein and
Sippl, 2007).
Results
Effects of deleting the cysteine-rich head
region on P2X1 receptor function
A signiﬁcant portion of the cysteine-rich head region of the
mammalian P2X receptors is absent from the antagonist-
insensitive Dictyostelium receptors. To determine whether this
region contributes to antagonist sensitivity at P2X1 receptors,
we generated a mutant receptor where the corresponding
region was deleted (P2X1 Del) (Figure 1). This deletion
mutant would be predicted to retain the disulphide pairing,
consistent with conserved cysteine residues 1–6 and provide
a constraint to the head region (Figure 2Bi). At WT P2X1
receptors, ATP (100 mM) evoked robust inward currents that
desensitized during the continued application of ATP (peak
amplitude -9188  590 nA, n = 12) consistent with previous
studies. In contrast, ATP (100 mM) evoked barely detectable
inward currents at P2X1 Del receptors (Figure 1C). Increasing
the concentration of ATP to 10 mM had no further effect on
the amplitude of responses at these mutant receptors (n = 4).
One possibility was that the six amino acids between the
cysteine residues (equivalent to 1 and 6 in mammalian recep-
tors) in the Dictyostelium receptor (p2xA, DDB0168616)
(Fountain et al., 2007) were important for folding and allow-
ing disulphide bond formation between the cysteine residues.
To test this hypothesis, we generated an additional deletion
mutant (DelD) in the P2X1 receptor where the six amino acid
residues between cysteines 1–6 were changed to those of the
Dictyostelium receptor. The DelD P2X1 receptor also had little
or no response to applied ATP (up to 10 mM). One explana-
tion for the lack of ATP-evoked current at Del and DelD P2X1
receptors could be that they are inefﬁciently made or traf-
ﬁcked to the cell surface. The WT P2X1 receptor was detected
in Western blots as a band of ~55 KDa corresponding to the
glycosylated form of the receptor (Roberts and Evans, 2004)
and was detected at the cell surface in a biotinylation assay.
Del and DelD P2X1 receptors were also detected by Western
blotting; however, they showed a decrease in molecular
weight, consistent with the removal of 42 amino acids
(Figure 1D). However the DelD has a higher molecular mass
than the Del mutant and this corresponds to the addition of
Figure 2
NF449 sensitivity at the P2X1 receptor chimeras swapping parts of
the cysteine-rich head region. (A) Sequence alignment of the
cysteine-rich loop region of human P2X1 and P2X2 receptors
showing the crossover points of the subdivided chimeras. (Bi)
Cartoon of the pairing of cysteine disulphide bonds in the head
region. (Bii) Homology model of the head region showing subdivi-
sion with the chimeras; P2X1 Cys2(1–3) chimera (blue), P2X1
Cys2(3–4) chimera (purple) and P2X1 Cys2(4–6) chimera (brown).
(C) Inhibition of ATP-evoked responses (EC90 concentration) by
NF449 (10 nM) at the chimeras dividing the head region. NF449 was
applied 5 min before the application of ATP and then co-applied with
ATP. (D) Concentration-dependent inhibition curves of the chimeras
by NF449 to an EC90 concentration of ATP. WT P2X1 and P2X2
receptor responses are shown with dotted lines for comparison
(n = 3).
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amino acid Dictyostelium linker that is absent from the Del
construct. Western blotting shows similar levels of total and
surface protein for P2X1 WT, Del and DelD receptors. These
results suggest that the lack of current at the Del and DelD
receptors does not result from a decrease in expression and
results from an effect on ATP binding to and/or opening/
gating of the receptor.
High NF449 sensitivity at the P2X1 receptor
is associated with the cysteine-rich
head region
An alternative approach to determine the role of the cysteine-
rich head in antagonist interaction was to generate a chimera,
swapping this region between an antagonist-sensitive and
antagonist-insensitive receptor. The antagonist NF449 is
effective in the nanomolar range at the P2X1 receptor but
>1000-fold less effective at P2X2 receptors (Rettinger et al.,
2005). A chimera was generated where the cysteine-rich head
region from the P2X2 receptor replaced that of the P2X1
receptor [P2X1 Cys2(1–6)] and characterized. ATP evoked
concentration-dependent inward currents at human P2X1
and P2X2 receptors with EC50 values of ~0.75 and 10 mM,
respectively, (n = 3–4, Supporting Information Table S1)
similar to those we have reported previously (Roberts et al.,
2008; 2009). P2X1 receptor currents showed marked desen-
sitization during the application of a maximal concentration
of ATP (100 mM ATP; time to 50% decay 495  45 ms, n = 17)
while in contrast, P2X2 receptor currents were maintained
during the 3 s application (no decay at end of 3 s pulse, n =
15). The P2X1 Cys2(1–6) chimera had similar peak current
amplitudes to the P2X1 receptor (n = 13, Supporting Infor-
mation Table S1) but ~fourfold decreased ATP potency (EC50
of ~3 mM, n = 3, P < 0.01) and slower desensitization (time to
50% decay of 1305  176 ms, n = 10, P < 0.01).
The antagonist action of NF449 was tested against a stan-
dardized EC90 concentration of ATP [10 mM for the P2X1
receptor and 30 mM for the P2X1 Cys2(1–6) chimera and the
P2X2 receptor]. NF449 inhibited ATP-evoked currents with an
IC50 of ~1 nM at the P2X1 receptor and ~1.5 mM at the P2X2
receptor (n = 3, P < 0.001, Figure 1, Supporting Information
Table S1). These sensitivities and ~1500-fold selectivity at the
P2X1 receptor compared with the P2X2 receptor is consistent
with previous reports (Rettinger et al., 2005). NF449 was an
antagonist at the P2X1 Cys2(1–6) receptor with an IC50 of
~0.3 mM (Figure 1, Supporting Information Table S1). The
~300-fold reduction in NF449 sensitivity (compared with
P2X1 WT, n = 3, P < 0.001) for the chimeric receptor indicates
that the cysteine-rich head region makes a signiﬁcant contri-
bution to NF449 sensitivity.
A cluster of positively charged residues in the
head region mediate NF449 selectivity for the
P2X1 receptor
To determine which part(s) of the cysteine-rich loop were
important for conferring NF449 sensitivity, three additional
chimeras, swapping regions of 16–18 amino acids with the
conserved cysteine residues as the crossover points, were gen-
erated (Figure 2A). They correspond to the ﬁrst to third (117
to 132), third to fourth (132 to 149) and fourth to sixth (149
to 165) conserved cysteine residues (P2X1 numbering).
Mapping these regions onto a homology model of the P2X1
receptor shows they correlate with the top [P2X1 Cys2(4–6)
chimera], middle [P2X1 Cys2(1–3) chimera] and bottom
[P2X1 Cys2(3–4) chimera] of the cysteine-rich head region
(Figure 2B). These additional chimeras all produced func-
tional P2X receptors with equivalent peak current amplitudes
to the P2X1 WT receptor (n = 12–15, Supporting Information
Table S1). ATP potency was reduced by ~threefold for these
chimeras (compared with P2X1 WT, n = 3–4, P < 0.05) similar
to that of the chimera swapping the whole of the cysteine-
rich head region (Supporting Information Table S1). The time
course of ATP currents at chimeras P2X1 Cys2(3–4) and P2X1
Cys2(4–6) were similar to WT P2X1 receptors (n = 7–10);
however, receptor desensitization for the P2X1 Cys2(1–3)
chimera was slowed ~twofold similar to the P2X1 Cys2
chimera (n = 8, P < 0.01, Supporting Information Table S1).
For the new chimeras, an EC90 concentration of ATP was used
to test for antagonist sensitivity. The sensitivity to NF449 for
the P2X1 Cys2(4–6) chimera (IC50 ~0.7 nM, n = 3, Figure 2C
and D) was the same as for the P2X1 WT receptor. NF449
sensitivity was reduced by ~20-fold at the P2X1 Cys2(1–3)
chimera (IC50 ~20 nM, n = 3, P < 0.001, Figure 2C and D).
Chimera P2X1 Cys2(3–4) showed a ~1700-fold decrease in
NF449 sensitivity compared with the P2X1 WT receptor and
was equivalent to that seen for the P2X2 receptor (IC50
~1850 nM, n = 3, P < 0.001, Figure 2C and D, Supporting
Information Table S1). NF449 produced a parallel rightward
shift in the concentration response to ATP at the P2X1
Cys2(3–4) chimera with no decrease in maximum response;
Schild analysis demonstrates the decrease in antagonist afﬁn-
ity was consistent with the change in IC50 value (Supporting
Information Figure S1).
The results from the chimeras indicate that the segment
between conserved cysteine residues 3–4 can account for the
difference in NF449 sensitivity between P2X1 and P2X2
receptors. This region of 18 amino acids contains seven con-
served and 11 variant amino acids. The antagonist NF449 is
negatively charged, suggesting that positively charged amino
acids may play a role in determining sensitivity. There are
four positively charged residues in the P2X1 receptor (K136,
K138, R139 and K140) that are absent from the P2X2 receptor
and, interestingly, two of these are negatively charged at the
P2X2 receptor (corresponding to K136 and K138). Mapping
these residues onto a P2X1 receptor homology model shows
that the side chains of these amino acids face towards the
groove below the cysteine-rich head region and pointing
away from the proposed ATP-binding pocket (Figure 3B). The
roles of the non-conserved positively charged residues in the
P2X1 receptor were tested by mutating them to the corre-
sponding residues in the P2X2 receptor (K136E, K138D,
R139M and K140L, Figure 3). The ATP potency of the point
mutations were similar to the WT P2X1 receptor (n = 3,
Supporting Information Table S1). NF499 (1 nM) reduced
currents evoked by an EC90 concentration of ATP (10 mM) by
~40–70% at K136E, R139M and K140L mutants similar to
that at the WT P2X1 receptor (n = 3–5, Figure 3C and D).
NF449 sensitivity at the K138D mutant was reduced ~10-fold
compared with the WT P2X1 receptor, with an IC50 of 10 nM
(Figure 3C and D, n = 3, P > 0.001 compared with P2X1 WT,
Supporting Information Table S1). However, the modest
BJP
S El-Ajouz et al.
394 British Journal of Pharmacology (2012) 165 390–400decrease in NF449 sensitivity for K138D did not correspond
with the 1700-fold decrease observed with the P2X1
Cys2(3–4) chimera. This suggests that a combination of the
positively charged residues may be important in coordinating
the action of NF449 at the P2X1 receptor.
To test whether the combination of charge was impor-
tant, four different P2X1 receptor mutants were constructed
in the ﬁve amino acid run K136-K140. The residues in the
P2X1 receptor were swapped to the equivalent ones in the
P2X2 receptor. The ﬁrst mutated the lysines 136 and 138 to
the corresponding negative charge in the P2X2 receptor
[KAKRK → EADRK(2)], the remainder of the mutants sequen-
tially removed the remaining positive charges [KAKRK →
EADRL(3)] [KAKRK → EADML(4)] and the ﬁnal variant
residue [KAKRK → ELDML(5)] (for summary data, see Sup-
porting Information Table S1). The peak current amplitudes
at all of these P2X1 receptor mutants were similar to the WT
P2X1 receptor (n = 8–14); however, the mutations reduced
ATP potency by threefold to 10-fold (n = 3, P = 0.001) and
desensitization was slower for the mutants KAKRK → EADML
and KAKRK → ELDML (n = 9–12, P < 0.001). Interestingly the
mutant ELDML had equivalent ATP sensitivity to the P2X2
receptor; however, it still showed rapid desensitization. These
results suggest that the region Cys2(3–4) can contribute to
agonist sensitivity at the P2X1 receptor. The double mutant
KAKRK , EADRK(2, had ~threefold reduced ATP potency
(n = 3, P > 0.01) but a similar time course to the P2X1 receptor
(n = 9). Sensitivity to NF449 was tested against an EC90 con-
centration of ATP for all the mutants. The double mutant
K136EK138D [KAKRK → EADRK(2)] shifted the NF449 inhi-
bition curve to the right compared with the K138D mutant
alone and resulted in an extra ~15-fold decrease in antagonist
sensitivity (IC50 ~0.15 mM, n = 3, P < 0.001 compared with the
K138K mutant, Figure 3D). Removing the other positively
charged lysine residue [the mutant KAKRK → EADRL(3)]
reduced the NF449 sensitivity by a further ~twofold (~150-
fold reduction compared with WT P2X1, IC50 0.31 mM,
Figure 3D, n = 3, P > 0.001 compared with WT P2X1). Addi-
tional mutation of the charged arginine residue [KAKRK →
EADML(4)], reduced NF449 sensitivity a further ~twofold
(~600-fold reduced compared with WT P2X1, IC50 ~0.56 mM,
Figure 3, n = 3, P > 0.001 compared with WT P2X1). Mutation
of the ﬁnal variant amino acid in the run 136–140 [an
alanine, KAKRK → ELDML(5)], produced a smaller decrease in
sensitivity (~700-fold reduction compared with WT P2X1, n =
3, P > 0.001) with an IC50 of 0.70 mM (Figure 3, Supporting
Information Table S1). These results suggest that a cluster of
positively charged residues at the base of the cysteine-rich
head region are important in mediating NF449 sensitivity at
the P2X1 receptor.
Suramin action on the P2X1 receptor
chimeras and mutants
At WT P2X1 receptors, suramin inhibited ATP-evoked cur-
rents (10 mMa nE C 90 concentration of ATP) with an IC50 of
~2 mM( n = 4, Figure 4, Supporting Information Table S1),
consistent with previous studies (Ennion et al., 2000). At
P2X2 receptors, responses to ATP (30 mM, an EC90 concentra-
tion) were only reduced by ~50% by 100 mM of the antagonist
(n = 4, Figure 4A, Supporting Information Table S1). These
results show that there is an ~60 fold difference between
human P2X1 and P2X2 receptors in their suramin sensitivity
(P < 0.001). As NF449 is a suramin analogue, it was of interest
to determine suramin sensitivity in the chimeras and point
mutations. Replacing the cysteine-rich loop of the P2X1
receptor with the P2X2 receptor [P2X1 Cys2(1–6) chimera]
reduced the suramin sensitivity by ~threefold compared with
the P2X1 receptor (pIC50 5.32  0.09, Figure 4A, Supporting
Figure 3
NF449 sensitivity at P2X1 receptor mutants. (A) Sequence alignment
of the residues 132–149 in the P2X1 and P2X2 receptor (P2X1
numbering). (B) Homology model of the P2X1 receptor zoomed in
on the head region showing the location of the proposed ATP-
binding pocket in red and the charged residues K136 (blue), K138
(purple), R139M (pink) and K140L (orange). (C) Inhibition of ATP-
evoked currents (EC90 concentration of ATP) in the absence (control)
and presence of NF449 (~IC50 concentration). NF449 was applied
5 min before the application of ATP and then co-applied with ATP.
(D) NF449 concentration-dependent inhibition curves of the P2X1
receptor mutants (against an EC90 concentration of ATP). WT P2X1
and P2X2 receptor responses are shown with dotted lines for com-
parison (n = 3).
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and ‘middle’ regions of the head loop [chimeras P2X1
Cys2(4–6) and P2X1 Cys2(1–3)] increased the suramin sensi-
tivity by threefold and 15-fold compared with the WT P2X1
receptor [IC50 ~0.56 and ~0.12 mM, Figure 4B, n = 3, P > 0.001
for P2X1 Cys2(1–3) chimera compared to WT P2X1, Support-
ing Information Table S1]. In contrast, the P2X1 Cys2(3–4)
chimera swapping the bottom part of the head region showed
suramin sensitivity more similar to the P2X2 receptor (IC50
~40 mM, Figure 4B, n = 3, P > 0.001 compared with WT P2X1,
Supporting Information Table S1). These results suggest that
the region between cysteine residues 3–4 contributes not only
to the difference in NF449 sensitivity but also to suramin
action.
The individual P2X1 receptor point mutations K136E,
R139M and K140L had no effect on suramin sensitivity (n = 3,
Figure 4C). However the K138D P2X1 receptor mutant
showed a ~threefold reduction in suramin sensitivity (IC50
~5.6 mM, n = 3, P < 0.05, Figure 4C, Supporting Information
Table S1). The double mutant K136EK138D [EADRK(2)]
further reduced suramin sensitivity by ~threefold compared
with K138D (IC50 15 mM, Figure 4C, n = 3, P < 0.01 compared
with K138D, Supporting Information Table S1). Removing
the third lysine [KAKRK → EADRL(3)] had the same suramin
sensitivity as the double mutant (IC50 19 mM, Figure 4C, n = 3,
P < 0.001 compared with WT P2X1, Supporting Information
Table S1). When the arginine, as well as the three lysine
residues, was replaced with the reciprocal residues in the
P2X2 receptor [KAKRK → EADML(4)], there was a further
~fourfold decrease in suramin sensitivity [IC50 70 mM, n = 3,
P > 0.01 compared to EADRL(3), Figure 4C, Supporting Infor-
mation Table S1]. Mutation of the other variant residue in
this region to give ELDML had no further effect on suramin
sensitivity (IC50 49 mM, Figure 4C, n = 3, P > 0.001 compared
with WT P2X1, Supporting Information Table S1). These
results suggest that the positively charged residues that were
involved in NF449 sensitivity also contributed to suramin
action.
Effects of reciprocal mutations at the P2X2
receptor on NF449 and suramin sensitivity
The chimeras and point mutants identiﬁed residues involved
in NF449 and suramin sensitivity at P2X1 receptors at the
base of the cysteine-rich head region. To test whether these
residues are sufﬁcient to account for the differences in sensi-
tivity to these antagonists between P2X1 and P2X2 receptors,
we generated a reciprocal chimera [P2X2 Cys1(3–4)] and
mutants in the P2X2 receptor (P2X2 D138K, E136KD138K,
ELDML→KLKMK and ELDML→KLKRK). Of these only the
D136K had an effect on ATP potency (threefold increase, EC50
3.87 mM, n = 3, P < 0.05, Supporting Information Table S2).
NF449 sensitivity at the P2X2 Cys1(3–4) chimera was
unchanged compared with the P2X2 receptor (IC50 1.1 mM);
however, suramin sensitivity was increased ~30-fold towards
that of the P2X1 receptor (IC50 4.3 mM, n = 3, P < 0.001
compared with WT P2X2, Figure 5 and Supporting Informa-
tion Table S2). The point mutation P2X2 D136K had no effect
on NF449 or suramin sensitivity. The double mutation
E134KD136K to reverse the charge at these positions resulted
in a modest increase in NF449 and suramin sensitivity (~two-
to three- and 10-fold, respectively, Figure 5A and C, Support-
Figure 4
Suramin sensitivity of P2X receptors, chimeras and mutants. Suramin
concentration-dependent inhibition curves against an EC90 concen-
tration of ATP for (A) P2X1 WT, P2X2 WT receptors and the P2X1
Cys2(1–6) chimera (B) The subdivided chimeras and (C) P2X1 recep-
tor mutants. In (B) and (C), WT P2X1 and P2X2 receptor responses
are shown with dotted lines for comparison. n = 3–4 for all data.
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residue [ELDML→KLKMK(3)] further increased both NF449
and suramin sensitivity (Figure 5B and D, Supporting Infor-
mation Table S2). Surprisingly, incorporating the additional
charged arginine residue [ELDML→KLKRK(4)] reduced NF449
and suramin sensitivity back to WT P2X2 receptor levels
(Figure 5C and D, Supporting Information Table S2). These
results further support the notion that the positive charge at
the bottom of the head region is important for sensitivity to
NF449 and suramin but that, in addition, other variant
residues/regions also contribute to subunit-dependent
antagonist selectivity.
Discussion
Mutagenesis and structural studies have established a model
of the P2X receptor ATP-binding site. Adjacent to this site is
a cysteine-rich ‘head’ region thought to be stabilized by three
disulphide bonds. In this study we have shown that this
cysteine-rich region is essential for normal channel function
at human P2X1 receptors and contributes to both agonist and
antagonist action.
Deletion mutants of the P2X1 receptor that removed the
cysteine-rich region essentially abolished functional
responses to ATP but had no effect on the trafﬁcking of the
receptor to the cell surface. Previous studies have shown that
alanine mutants of conserved cysteine residues in the head
region reduced ATP potency (Clyne et al., 2002; Ennion and
Evans, 2002) and the EC50 for ATP at Dictyostelium receptors is
in the 100–500 mM range (Ludlow et al., 2009), raising the
possibility that the head region may contribute to agonist
sensitivity. Our results suggest that the cysteine-rich head
region is essential for the normal functioning of mammalian
P2X receptors and highlights a difference from the Dictyoste-
lium P2X receptor family where it is absent.
The generation and characterisation of chimeric receptors
demonstrated that the cysteine-rich head region plays an
important role in antagonist action at P2X receptors. This
ﬁnding may provide an explanation of why Dictyostelium P2X
receptors, which lack the head region, are insensitive to com-
monly used purinergic receptor antagonists (Fountain et al.,
2007; Ludlow et al., 2009). In particular, swapping the base
region of the head [chimera P2X1 Cys2(3–4)] switched sen-
sitivity to both NF449 and suramin from that of the P2X1 to
the P2X2 receptor. One distinguishing feature within this
base region is the four positively charged residues in the P2X1
receptor that are absent from other family members. Both
suramin and NF449 are negatively charged (six and eight
negative charges, respectively, associated with the polysul-
phonates) and positively charged residues have been shown
Figure 5
NF449 and suramin sensitivity at P2X2 receptor chimeras and
mutants. (A) Sequence alignment of the human P2X1 and P2X2
receptors from the residues 132 to 149. (B) NF449 sensitivity of the
X2-KLKMK(3) and D136K P2X2 receptor mutants. (C) NF449 sensi-
tivity of the P2X2 Cys1(3–4) chimera and X2-KLKRK(4) P2X2 recep-
tor mutant. (D) Suramin sensitivity of the P2X2 Cys1(3–4) chimera
and P2X2 receptor mutants. For (B) to (D), the antagonists were
tested on an EC90 concentration of ATP. WT P2X1 and P2X2 receptor
responses are shown with dotted lines for comparison. n = 3–4 for all
data.
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(Ganesh et al., 2005; Schuetz et al., 2007; Zhou et al., 2008).
The reduction in NF449 (~10-fold) and suramin (~three-
fold) sensitivity for the K138D P2X1 receptor mutant is con-
sistent with a previous report identifying the role of this
residue in mediating the modest species differences in sensi-
tivity to these antagonists between mouse and human P2X1
receptors (Sim et al., 2008). The chicken P2X1 receptor also
showed reduced sensitivity to suramin, but the molecular
basis of this difference was not determined. Interestingly at
position 138, the lysine found in the human receptor is
replaced by an asparagine residue (Soto et al., 2003), suggest-
ing that this difference may underlie the difference in antago-
nist sensitivity. Similarly, at the P2X7 receptor, suramin is
~10-fold more effective at the guinea pig compared with the
rat and human isoforms and has additional lysine residues in
the base region of the cysteine-rich loop (Fonfria et al., 2008).
Characterization of the effects of multiple mutants within
the positively charged base region of the cysteine-rich loop
demonstrated a sequential decrease in NF449 and suramin
sensitivity. These results indicate that the combination of
positive charges is important in the regulation of antagonist
sensitivity at the P2X1 receptor and may reﬂect the highly
charged nature of NF449 and suramin. The corresponding
reciprocal mutations in the P2X2 receptor resulted in, at best,
a modest 10-fold increase in NF449 sensitivity. This suggests
that it is not just the positive charge at the base of the P2X1
receptor head region that is important for mediating high
afﬁnity binding of NF449 but also a more complex interac-
tion with other variant residues. It is likely that other parts of
the cysteine-rich head group contribute to these differences
as the chimera P2X1 Cys2(1–3) (above the positive charge-
rich base region) reduced NF449 sensitivity by 10-fold.
The cysteine-rich head region is adjacent to the proposed
ATP-binding site. This raises the possibility that a combina-
tion of positive charges at the base of the head region, along
with the conserved lysine and arginine residues in the ATP-
binding pocket, coordinate the docking of NF449. This would
provide a site for NF449 and ATP to compete for receptor
occupancy as shown by the competitive action of NF449 at
the human P2X1 receptor (Hulsmann et al., 2003). Support
for this idea comes from a mutant P2X2 receptor where
suramin can act as a weak partial agonist (Cao et al., 2007)
and recent in silico docking simulations at the P2X2 receptor
that predicted that suramin-based antagonists bind within
the proposed ATP-binding pocket (Wolf et al., 2011). The
modelling makes sense as one would predict that the multiple
negative charges on the suramin-based antagonists are likely
to be coordinated by multiple positive charges. The greatest
concentration of positive charge in the receptor is associated
with the predicted ATP-binding pocket and this would be
scored highly by the ligand-docking algorithms. However,
the P2X2 receptor in silico predictions remain to be tested
experimentally. The model predicts that the equivalent P2X1
receptor residues K70, R292 and K309 that are involved in
ATP potency also mediate antagonist action. Our previous
studies indicate that alanine mutation of these residues
decreased ATP potency up to 1000-fold but either had no
effect (K68, K70A and K309A) or only a small ~threefold
reduction (R292A) in suramin sensitivity (Ennion et al., 2000)
suggesting these residues do not play a major role in suramin
action, although the effects on the sensitivity to suramin
derivatives have not been determined. It may be that, as seen
for NF449 sensitivity, individual charge change may only
have a small effect, and combinations of charges need to be
mutated to see a large reduction in antagonist action.
However this may be difﬁcult to test experimentally as muta-
tion of several positive charges in the ATP-binding pocket are
also likely to have a major effects on agonist action.
There are two possible anomalies to the model of NF449
binding between the ATP pocket and the base of the head
region. Firstly, the residue K138 (the only sole point mutation
that reduced NF449 sensitivity) points away from the pro-
posed ATP-binding site in the P2X1 receptor homology
model. However, caution needs to be taken in interpreting
the model, as the electron density for this region was weak in
the crystal (Kawate et al., 2009). In addition, the structure
provides a snapshot of one state of the receptor and may not
reﬂect directly the mode in which NF449 binds. Secondly,
analysis of species differences in antagonist action at the
P2X4 receptor demonstrates that residue 78 plays a role in
suramin sensitivity (Garcia-Guzman et al., 1997). This residue
is neither part of the predicted ATP-binding pocket, nor the
cysteine-rich head region but sits at the apex of the receptor
where the three subunits come together to form the opening
to the upper vestibule. This raises the possibility that the
antagonist may not bind at the ATP site or that conforma-
tional changes in the receptor dependent on the apex region
play a signiﬁcant role in antagonist sensitivity. Further
studies will be required to determine the full extent of the
suramin and NF449 binding sites.
In summary the present study has shown that a cluster of
positively charged residues at the base of the cysteine-rich
head region are responsible for the nanomolar sensitivity and
high selectivity of the antagonist NF449 at P2X1 receptors.
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Supporting information
Additional Supporting Information may be found in the
online version of this article:
Figure S1 Schild analysis of antagonism by NF449 at WT
P2X1 receptors and the P2X1Cys2(3–4) chimera. The pA2
estimate for the WT receptor was ~9.9, with a slope of 1.17 
0.16 (n = 6–14 for each concentration). For the
P2X1Cys2(3–4) chimera the pA2 estimate was ~6.4 with a
slope of 0.84  0.02 (n = 3 for each concentration).
Table S1 Properties of P2X1 receptor chimeras and mutants.
Effects of the P2X1 chimeras and mutants on the peak
current, rise time, decay time, ATP potency, Hill slope, NF449
and suramin sensitivity. Peak current values taken on the ﬁrst
application of a maximal concentration of ATP (100 or
300 mM). Rise time represents the time from 10 to 90% of the
peak current and decay time represents the time 100 to 50%
decay of the current. pEC50 values calculated from the indi-
vidual concentration response curves. pEC50 is -log10 of the
EC50 for ATP. Hill coefﬁcient of the ﬁtted curves is shown.
pIC50 calculated from the individual inhibition curves. pIC50
is -log10 of the IC50 for the antagonist. Values are the mean
 SEM. Signiﬁcant differences from WT P2X1 receptors are
indicated in bold, *P < 0.05 **P < 0.01 ***P < 0.001 measured
by one-way ANOVA, n = 3 to 10, ND, not determined.
Table S2 Properties of P2X2 receptor chimeras and mutants.
Effects of the P2X2 chimeras and mutants on the peak
current, ATP potency, Hill slope, NF449 and suramin sensi-
tivity. Peak current values taken on the ﬁrst application of a
maximal concentration of ATP. pEC50 values calculated from
the individual concentration response curves. pEC50 is -log10
of the EC50 for ATP. Hill coefﬁcient of the ﬁtted curves is
shown. pIC50 calculated from the individual inhibition
curves. pIC50 is -log10 of the IC50 for the antagonist. Values
are the mean  SEM. Signiﬁcant differences from WT P2X2
receptors are indicated in bold, *P < 0.05 **P < 0.01 ***P <
0.001 measured by one-way ANOVA, n = 3 to 10, ND, not
determined
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